Home
Covid-19
Tools
Introduction to the Tools
Model Government Use Licences
Model Uses of Paragraph 7 or “LDC Waiver”
Special Compulsory Licences for Export of Medicines
Options for Regional Economic Communities
Voluntary Licences
TRIPS Flexibilities Database
Resources
Briefs & Briefing Documents
Publications
Tools
Useful Links
All Resources
Blog
About
Search
Medicines Law & Policy
Research and resources on intellectual property and health
Home
Covid-19
Tools
Introduction to the Tools
Model Government Use Licences
Model Uses of Paragraph 7 or “LDC Waiver”
Special Compulsory Licences for Export of Medicines
Options for Regional Economic Communities
Voluntary Licences
TRIPS Flexibilities Database
Resources
Briefs & Briefing Documents
Publications
Tools
Useful Links
All Resources
Blog
About
Tag: WHO
The € 7.4 billion for Covid-19 product and vaccine development needs...
Ellen 't Hoen
-
May 5, 2020
Covid-19 intellectual property pool gaining support
Ellen 't Hoen
-
April 23, 2020
Urgent collective action to meet the challenge of this pandemic crisis:...
Christopher Garrison
-
March 30, 2020
Wrapping up 2019 – Noteworthy Medicines Law and Policy Events
Ellen 't Hoen
-
December 30, 2019
Drug Price Transparency Calls Move from South Africa to World Health...
Medicines Law & Policy
-
May 18, 2019
Strong call for transparency on medicine prices, cost of R&D at...
Ellen 't Hoen
-
April 19, 2019
Cancer Drug Pricing on the World Health Organization’s Executive Board Agenda
Ellen 't Hoen
-
January 23, 2019
2018 Round-up of Noteworthy Medicines Law and Policy Events
Ellen 't Hoen
-
December 26, 2018
WIPO and pharma industry launch global medicines patent database
Ellen 't Hoen
-
September 27, 2018
The Power of TRIPS Flexibilities in Medicines Procurement
Ellen 't Hoen
-
April 9, 2018
1
2
3
4
Page 3 of 4
This work is licensed under Creative Commons.